More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.02B
EPS
-3.12
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.24184
Previous close
$30.16
Today's open
$30.05
Day's range
$28.44 - $30.52
52 week range
$10.46 - $49.70
show more
CEO
Robert Barrow
Employees
105
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
136899935
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Definium Therapeutics held $1.05 billion in cash on Sept. 30, 2026. Management expects cash resources to fund planned operations into 2030.
The Motley Fool • Nov 16, 2026

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said.
MarketBeat • Nov 11, 2026

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated
Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and is preparing for a potential commercial launch in 2027. Despite class-leading efficacy data and regulatory momentum, I maintain a Hold rating due to high valuation, patent challenges, and uncertain market dynamics.
Seeking Alpha • Nov 10, 2026

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 10, 2026

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements obser.
Business Wire • Nov 9, 2026

Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 20.
Business Wire • Nov 9, 2026

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO. Positive topline results from Panorama, the Company's second Phase 3 study of DT120 (lysergide.
Business Wire • Nov 4, 2026

Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc.
Business Wire • Nov 3, 2026

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.Listeners can register for the webcast via this link.
Business Wire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Definium Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.